December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
The final month of 2018 will see FDA verdicts on Roche’s bid to play in the first-line lung cancer space, and what Jazz hopes will be its next big narcolepsy product.
Cell and gene therapy companies dominate the first quarter, but companies outside these fashionable areas are finding it harder to charm VCs.
Demand for new issues remains sluggish - only eight private biotechs managed to pull off an IPO in the first quarter of 2017.